Bristol Myers Squibb is executing a visible portfolio transition, with its Growth Portfolio now surpassing Legacy Portfolio.
If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second lineCHMP recommendation ...
Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of ...
Can I no longer use new drugs after starting dialysis?As you continue treatment for myeloma, your kidney function may decline ...
Related reads:تشارلي كوكس يتحدث عن عودة The Defenders: "كان لا بد من تقديم خاتمة للقصة" في حديثه مع IGN خلال معرض New York Comic Con 2026، وصف فين جونز، ممثل شخصية Iron Fist، عودته إلى عالم مارفل السي ...
Clinical Trials Arena on MSN
BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial
BMS’s Zenbexus gained FDA approval based on a previous primary endpoint being achieved in the same trial.
BMS Reports Iberdomide Combination Reduces Risk of Progression or Death by 51% in Relapsed or Refractory Multiple Myeloma / ...
InvestorsHub on MSN
Natera launches phase III MRD-guided breast cancer trial using Signatera
AFT-70 NAVIGATE will test whether Signatera-guided treatment can reduce unnecessary CDK4/6 inhibitor exposure while maintaining outcomes in more than 2,000 patients. Key Investor Takeaways ・Natera ...
Those questions point to research that is still needed, Nieva says. This includes the role of deintensifying imaging and ...
Chris Blankenship’s retirement caps an ADCNR career that brought $525 million in outdoor improvements and more than 110,000 acres of protected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results